SEC Form 4 · accession 0001493152-17-012292
Medovex Corp. · MDVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jesse Crowne
Director
Period of report
Oct 30, 2017
Accepted (ET)
Nov 1, 2017 · 6:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001591165
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 30, 2017 | A | 2,137 | $1.17 | A | 169,100 | D | |
| Common StockF2 | Oct 30, 2017 | A | 31,240 | $1.08 | A | 200,340 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person was granted 2,137 shares of common stock in lieu of cash fees that were due to the Reporting Person as of September 30, 2017 for his board services. The number of shares issued is based on the accrued but unpaid director fees owed to the Reporting Person during the nine months ended 2017, divided by the average closing price of the Issuer's common stock during the nine months ended 2017.
- F2The Reporting Person was granted a restricted stock award of 125,000 shares (the "RSA") pursuant to the Issuer's 2013 Stock Option Incentive Plan. The shares fully vest over a two year period as follows: 25% on the grant date; 25% on the first anniversary of the grant; and 50% on the second anniversary of the grant. The number of shares issued represents the vested portion of the RSA.